Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Assets (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Assets for 10 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets rose 1.93% to $1.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 billion, a 1.93% increase, with the full-year FY2025 number at $1.5 billion, up 1.93% from a year prior.
  • Assets was $1.5 billion for Q4 2025 at Ultragenyx Pharmaceutical, up from $1.2 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.6 billion in Q3 2022 to a low of $1.2 billion in Q3 2025.
  • A 5-year average of $1.4 billion and a median of $1.5 billion in 2021 define the central range for Assets.
  • Peak YoY movement for Assets: grew 29.57% in 2021, then dropped 23.5% in 2023.
  • Ultragenyx Pharmaceutical's Assets stood at $1.5 billion in 2021, then grew by 1.51% to $1.5 billion in 2022, then dropped by 3.52% to $1.5 billion in 2023, then grew by 0.8% to $1.5 billion in 2024, then grew by 1.93% to $1.5 billion in 2025.
  • Per Business Quant, the three most recent readings for RARE's Assets are $1.5 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.3 billion (Q2 2025).